
Sign up to save your podcasts
Or
With incredible medical advances, some people that were considered to have multiple sclerosis are now diagnosed with neuromyelitis optica (NMO) and MOG Antibody Disease (MOGAD). Dr. Sean Pittock from Mayo Clinic shares how NMO and MOGAD are different from multiple sclerosis and reviews the alternate approaches to treatment including the 3 FDA-approved treatments for NMO, Soliris (eculizumab), Uplinza (inebilizumab) and Enspyrng (satralizumab). Latest research in screening spinal fluid and blood for clues of multiple sclerosis discussed to improve diagnosis and monitoring of the disease.
Barry Singer MD, Director of The MS Center for Innovations in Care, interviews:
Daniel Reich MD PhD is the Chief of the Translational Neuroradiology Section of the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH). He obtained his undergraduate degree in math and physics at Yale, PhD in neuroscience at The Rockefeller University and MD degree at Cornell. Dr. Reich completed residencies in both neurology and diagnostic radiology and a neuroradiology fellowship at John Hopkins Hospital.
Sean Pittock MD is a Professor of Neurology at Mayo Clinic. His is the Director of Mayo Clinic's Center for Multiple Sclerosis and Autoimmune Neurology and Director of Mayo's Neuroimmunology Research Laboratory. He earned his medical degree from University College Dublin, post-doctoral degree at the Royal College of Surgeons in Ireland followed by residency and fellowship at Mayo Clinic in Rochester, Minnesota.
Visit www.mslivingwell.org for more information.
Share your MS story on https://ICanWithMS.org
4.9
114114 ratings
With incredible medical advances, some people that were considered to have multiple sclerosis are now diagnosed with neuromyelitis optica (NMO) and MOG Antibody Disease (MOGAD). Dr. Sean Pittock from Mayo Clinic shares how NMO and MOGAD are different from multiple sclerosis and reviews the alternate approaches to treatment including the 3 FDA-approved treatments for NMO, Soliris (eculizumab), Uplinza (inebilizumab) and Enspyrng (satralizumab). Latest research in screening spinal fluid and blood for clues of multiple sclerosis discussed to improve diagnosis and monitoring of the disease.
Barry Singer MD, Director of The MS Center for Innovations in Care, interviews:
Daniel Reich MD PhD is the Chief of the Translational Neuroradiology Section of the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH). He obtained his undergraduate degree in math and physics at Yale, PhD in neuroscience at The Rockefeller University and MD degree at Cornell. Dr. Reich completed residencies in both neurology and diagnostic radiology and a neuroradiology fellowship at John Hopkins Hospital.
Sean Pittock MD is a Professor of Neurology at Mayo Clinic. His is the Director of Mayo Clinic's Center for Multiple Sclerosis and Autoimmune Neurology and Director of Mayo's Neuroimmunology Research Laboratory. He earned his medical degree from University College Dublin, post-doctoral degree at the Royal College of Surgeons in Ireland followed by residency and fellowship at Mayo Clinic in Rochester, Minnesota.
Visit www.mslivingwell.org for more information.
Share your MS story on https://ICanWithMS.org
7,189 Listeners
7,327 Listeners
142 Listeners
406 Listeners
9,353 Listeners
7,928 Listeners
47 Listeners
1,813 Listeners
84 Listeners
279 Listeners
9 Listeners
350 Listeners
111 Listeners
20,416 Listeners
3,516 Listeners